Drug
LB100 clinical trials
Also written LB-100.
- studies test it
- 6
- open now
- 3
- in phase 3
- 0
- first study started
- 2013
Keep track of what changes. Save the LB100 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 4
Lixte Biotechnology Holdings, Inc. (2) · City of Hope Medical Center (1) · National Cancer Institute (NCI) (1) · The Netherlands Cancer Institute (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Atezolizumab (2) · Carboplatin (1) · Etoposide (1) · Docetaxel (1) · Dostarlimab (1)
Studies
Open first, then newest update. How each study uses LB100 is read from its arms, and is right about nine times in ten.
Testing it · 6
- LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsRecruitingPhase 1The Netherlands Cancer InstituteNCT06012734Written as LB-100
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06065462Written as LB-100
- A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)RecruitingPhase 1/2Lixte Biotechnology Holdings, Inc.NCT03886662Written as LB-100
- LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingPhase 1City of Hope Medical CenterNCT04560972Written as Protein Phosphatase 2A Inhibitor LB-100
- Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedPhase 2National Cancer Institute (NCI)NCT03027388Written as LB-100
- Phase I Study of LB-100 With Docetaxel in Solid TumorsCompletedPhase 1Lixte Biotechnology Holdings, Inc.NCT01837667Written as LB-100 for Injection
Codes
What other systems call LB100 · ClinicalTrials.gg INT001362
- MeSH (NLM) C000708580LB100One source ClinicalTrials.gov
- UNII (FDA) 0C1JUU9S0LLB-100Confirmed FDA, Wikidata
- Wikidata Q27895894LB100Confirmed FDA, Wikidata
- DrugBank DB15412One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708580 | LB100 | One source ClinicalTrials.gov |
| UNII (FDA) | 0C1JUU9S0L | LB-100 | Confirmed FDA, Wikidata |
| Wikidata | Q27895894 | LB100 | Confirmed FDA, Wikidata |
| DrugBank | DB15412 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.